Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-1991

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-1991). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, showing the molecular arrangement including a naphthalene group, thiophene ring, and an amine group with hydrochloride (HCl).*

FDA Label Image

Figure 1 (Duloxetine 02)

Kaplan-Meier curve comparing the proportion of patients experiencing relapse over time from randomization (days) between Duloxetine delayed-release capsules and placebo. The graph shows relapse proportion on the vertical axis and time in days on the horizontal axis, with Duloxetine treatment curve consistently below placebo.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time in days from randomization for a comparison between placebo and Duloxetine delayed-release capsules. The y-axis represents the proportion of patients with relapse, and the x-axis represents time in days up to 300. The graph displays separate curves for placebo and Duloxetine delayed-release capsules treatment groups.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: DULOXETINE HYDROCHLORIDE 60 mg BID, 60 mg QD, 20 mg QD, and placebo, showing varying degrees of pain improvement across the groups.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and a placebo. Both Duloxetine groups show similar and higher improvement percentages compared to placebo across the range of pain improvement from 0% to 100%.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine (DUL) 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph compares the effectiveness of the treatments in pain improvement over a range of percent improvements from greater than 0 to 100.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Four groups are compared: Duloxetine (DUL) 20 mg, 60 mg, and 120 mg once daily, and placebo. The x-axis represents percent improvement in pain, from 0 to 100, and the y-axis shows the percentage of patients improved, from 0 to 100%. The graph shows decreasing percentages of patients as percent improvement increases for all groups.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved over varying levels of percent improvement in pain from baseline (BOCF) between placebo and Duloxetine (60/120 mg once daily). The y-axis shows the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from 0 to 100 percent.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline on the x-axis. Two data series are shown: placebo and Duloxetine 60 mg once daily, tracking patient improvement percentages across incremental pain improvement levels from greater than 0% to 100%.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and duloxetine 60/120 mg once daily. The graph shows a decreasing trend in patient improvement as percent pain improvement increases, with duloxetine consistently showing higher percentages of patient improvement than placebo.*

FDA Label Image

Label (Lbl636291991)

Label for Duloxetine Delayed-Release Capsules, USP 30 mg by Bryant Ranch Prepack. The label shows the NDC 63629-1991-1 and states the product contains 30 mg Duloxetine Hydrochloride per capsule. It includes storage instructions and a quantity of 90 capsules. The label features the BRP Pharmaceuticals logo and indicates prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.